Quantitative T2* magnetic resonance imaging for evaluation of iron deposition in the brain of β-thalassemia patients

Clinical Neuroradiology

Volumn 22, Issue 3, 2012, Pages 211-217

  Akhlaghpoor, S ^a,b   Ghahari, A ^a,c   Morteza, A ^c   Khalilzadeh, O ^c   Shakourirad, A ^a   Alinaghizadeh, M R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Noor Medical Imaging Center   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beta Thalassemia; Ferritin; Iron deposition; Magnetic resonance imaging; T2 relaxation time; T2*Value

Indexed keywords

FERRITIN; IRON;

ADENOHYPOPHYSIS; ADULT; ARTICLE; BASAL GANGLION; BETA THALASSEMIA; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; THALAMUS; THALASSEMIA MAJOR; ALGORITHM; BRAIN; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; IRON OVERLOAD; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; ALGORITHMS; BETA-THALASSEMIA; BRAIN; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IRON OVERLOAD; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84866412289     PISSN: 18691439     EISSN: 18691447     Source Type: Journal    
DOI: 10.1007/s00062-011-0108-z     Document Type: Article

References (39)

1. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42:247-51. Epub 2009 Feb 23.
2. Papadimas J, Mandala E, Pados G, Kokkas B, Georgiadis G, Tarlatzis B, et al. Pituitary-testicular axis in men with beta-thalassaemia major. Hum Reprod. 1996;11:1900-4.
3. Sparacia G, Iaia A, Banco A, D'Angelo P, Lagalla R. Transfusional hemochromatosis: quantitative relation of MR imaging pituitary signal intensity reduction to hypogonadotropic hypogonadism. Radiology. 2000;215:818-23.
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-73.
5. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29:909-17.
6. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-7.
7. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-31.
8. Kovesdy CP, Estrada W, Ahmadzadeh S, Kalantar-Zadeh K. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:435-41.
9. Walker EM Jr, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000;30:354-65.
10. van Gelder W, Huijskes-Heins MI, Cleton-Soeteman MI, van Dijk JP, van Eijk HG. Iron uptake in blood-brain barrier endothelial cells cultured in iron-depleted and iron-enriched media. J Neurochem. 1998;71:1134-40.
11. Metafratzi Z, Argyropoulou MI, Kiortsis DN, Tsampoulas C, Chaliassos N, Efremidis SC. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol. 2001;74:407-10.
12. Safarinejad MR. Evaluation of semen quality, endocrine profile and hypothalamus-pituitary-testis axis in male patients with homozygous beta-thalassemia major. J Urol. 2008;179:2327-32.
13. Stark DD, Bass NM, Moss AA, Bacon BR, McKerrow JH, Cann CE, et al. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology. 1983;148:743-51.
14. Ghugre NR, Coates TD, Nelson MD, Wood JC. Mechanisms of tissue- iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med. 2005;54:1185-93.
15. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-55.
16. Bizzi A, Brooks RA, Brunetti A, Hill JM, Alger JR, Miletich RS, et al. Role of iron and ferritin in MR imaging of the brain: a study in primates at different field strengths. Radiology. 1990;177:59-65.
17. Hirai T, Korogi Y, Sakamoto Y, Hamatake S, Ikushima I, Takahashi M. T2 shortening in the motor cortex: effect of aging and cerebrovascular diseases. Radiology. 1996;199:799-803.
18. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-62.
19. Meloni A, Ramazzotti A, Positano V, Salvatori C, Mangione M, Marcheschi P, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Int J Med Inform. 2009;78:503-12.
20. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.
21. Argyropoulou MI, Metafratzi Z, Kiortsis DN, Bitsis S, Tsatsoulis A, Efremidis S. T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major. AJR Am J Roentgenol. 2000;175:1567-9.
22. Xu X, Wang Q, Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage. 2008;40:35-42.
23. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41-51.
24. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25:1147-51.
25. Positano V, Salani B, Pepe A, Santarelli MF, De Marchi D, Ramazzotti A, et al. Improved T2* assessment in liver iron overload by magnetic resonance imaging. Magn Reson Imaging. 2009;27:188-97.
26. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Multicenter validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006;91:1388-91.
27. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem. 1994;63:793-807.
28. Schenker C, Meier D, Wichmann W, Boesiger P, Valavanis A. Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology. 1993;35:119-24.
29. Wood JC, Fassler JD, Meade T. Mimicking liver iron overload using liposomal ferritin preparations. Magn Reson Med. 2004;51:607-11.
30. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-6.
31. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115:106-8.
32. Argyropoulou MI, Kiortsis DN, Efremidis SC. MRI of the liver and the pituitary gland in patients with beta-thalassemia major: does hepatic siderosis predict pituitary iron depositioñ Eur Radiol. 2003;13:12-6.
33. Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci. 2010;1202:123-8.
34. Al-Rimawi HS, Jallad MF, Amarin ZO, Obeidat BR. Hypothalamic- pituitary-gonadal function in adolescent females with betathalassemia major. Int J Gynaecol Obstet. 2005;90:44-7.
35. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res. 2002;1:72-9.
36. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, Schroter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr. 1997;156:777-83.
37. Nielsen JE, Jensen LN, Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry. 1995;59:318-21.
38. Schroder J, Haan J. Extrapyramidal syndrome in idiopathic hemochromatosis. Significance of laboratory chemical, neurophysiologic and imaging procedures (CCT, MRT). Nervenarzt. 1987;58:577-8.
39. Argyropoulou MI, Kiortsis DN, Astrakas L, Metafratzi Z, Chalissos N, Efremidis SC. Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study. Eur Radiol. 2007;17:3025-30.